Merck-Ridgeback COVID drug cuts hospitalizations, deaths by 50%

Friday, 01. October 2021 12:24

Molnupiravir, an investigational oral medicine against COVID-19 developed by Merck & Co. Inc. and Ridgeback Biotherapeutics, "reduced the risk of hospitalization or death by approximately 50%" in the phase three trial, the companies announced on Friday.

Just under 1,550 patients who had a mild-to-moderate disease and at least one risk factor were involved in the study. "Efficacy was not affected by timing of symptom onset or underlying risk factor" and "molnupiravir demonstrated consistent efficacy across viral variants Gamma, Delta, and Mu," it was said in the press release.

Merck intends to seek Emergency Use Authorization (EUA) from the United States Food and Drug Administration "as soon as possible" and "expects to produce 10 million courses of treatment by the end of 2021" if it receives approval for the drug.

Related Links: Merck & Co. Inc.
Author:
Baha Breaking the News (BBN) / MS